Pharmacologic, not energy medicine: an established anesthetic gas; its neuroprotection / longevity claims are frontier (grade C). Classified under Pharmacologic / redox agents because its action is receptor / anesthetic pharmacology, not gas-pressure physiology.
Origin & lineage
Noble gas; established anesthetic with neuroprotective research interest.
Claimed mechanism
Receptor-level (NMDA-antagonist) neuroprotection / anti-apoptotic action; general anesthesia.
Plausibility
Plausible biologically; narrow and costly.
Evidence — grade C
Established for anesthesia; non-anesthesia (neuroprotection / longevity) is grade C.
Market
Makers: Hospital anesthesia gas systems. Models: Medical xenon (anesthesia). Price: High cost.
Kernel — keep vs set aside
Keep — real substrate
Real anesthesia / pharmacology research.
Set aside — claim
'Frequency' / energy-medicine framing is misleading; neuroprotection / longevity uses are not established.
Regulatory status by jurisdiction
Registration or clearance is a market-access fact, never proof of efficacy.
US — FDA
Regulated medical gas (anesthesia); neuroprotection / longevity uses not cleared.
EU — MDR
Regulated medical gas (anesthesia).
Russia
Not specified in source.
China — NMPA
Not specified in source.
Australia — TGA
Not specified in source.
Sources
No verified primary source available — claims carried as unverified; not fabricated.